Home Ingredients SAMe (S-Adenosyl-L-Methionine)
CognitiveLiver HealthDetox & CleanseJoint HealthMood & Mental Health

SAMe (S-Adenosyl-L-Methionine)

Evidence Level
Moderate
4 Clinical Trials
6 Documented Benefits
3/5 Evidence Score

S-Adenosyl-L-Methionine (SAMe) is a naturally occurring compound in the body, synthesized from methionine and adenosine triphosphate (ATP). It plays a critical role in methylation processes, supporting neurotransmitter synthesis, liver detoxification, and joint health. As a dietary supplement, SAMe is used to improve mood, alleviate depression symptoms, support liver function, and reduce osteoarthritis pain. Typical doses range from 400–1600 mg daily, but effects vary, and it may cause side effects like nausea or insomnia. SAMe may interact with antidepressants or other medications. Consult a healthcare provider before use, especially with medical conditions or concurrent medications.

Studied Dose 400–800 mg/day for depression; 600–1,200 mg/day for osteoarthritis; taken on empty stomach
Active Compound S-Adenosyl-L-Methionine

Benefits

Mood and Depression Support

SAMe may help alleviate symptoms of depression by supporting neurotransmitter production, such as serotonin and dopamine. Studies suggest it can be as effective as some antidepressants for mild-to-moderate depression, with fewer side effects.

Supported by Trial 1, Trial 2

Joint Health and Osteoarthritis

SAMe has anti-inflammatory properties and may stimulate cartilage growth, potentially reducing pain and improving mobility in people with osteoarthritis, particularly in the knees.

Supported by Trial 3, Trial 1

Liver Function

SAMe supports liver health by aiding in detoxification and protecting against liver damage. It may benefit conditions like cholestasis, non-alcoholic fatty liver disease, and hepatitis.

Supported by Trial 3, Trial 4

Cognitive Health

Preliminary research indicates SAMe may support cognitive function and could have a role in managing symptoms of conditions like Alzheimer’s disease, though more studies are needed.

Supported by Trial 2, Trial 3

Fibromyalgia

Some evidence suggests SAMe may reduce pain, fatigue, and stiffness in people with fibromyalgia.

Supported by Trial 3, Trial 1

Methylation Support

SAMe is a key methyl donor in the body, supporting DNA repair, gene expression, and detoxification processes, which are critical for overall health.

Supported by Trial 4, Trial 1

Mechanism of action

1

Methylation Reactions

SAMe is a universal methyl donor, transferring methyl groups to molecules like DNA, proteins, phospholipids, and neurotransmitters. Modifies DNA and histones to control gene activity. Supports production of serotonin, dopamine, and norepinephrine, impacting mood and cognitive function. Methylates phospholipids, maintaining cell membrane integrity. Facilitates the metabolism of toxins and drugs in the liver.

2

Transsulfuration Pathway

SAMe is converted into homocysteine, which enters the transsulfuration pathway to produce glutathione, a potent antioxidant. Enhances detoxification and reduces oxidative stress in conditions like fatty liver disease or hepatitis. Protects cells from oxidative damage.

3

Polyamine Synthesis

SAMe contributes to the synthesis of polyamines. Supports tissue regeneration, including cartilage in osteoarthritis. May aid in maintaining neuronal health.

4

Anti-inflammatory Effects

SAMe reduces pro-inflammatory cytokines (e.g., TNF-α) and increases anti-inflammatory mediators. This contributes to pain relief and improved joint function in osteoarthritis and symptom relief in fibromyalgia.

5

Neurotransmitter Modulation

By supporting methylation, SAMe enhances the synthesis and metabolism of neurotransmitters, which may explain its antidepressant effects and potential benefits in cognitive disorders.

Clinical trials

1
SAMe as SSRI Augmentation for Depression — RCT
PubMed

Randomized, double-blind, placebo-controlled trial (NCT00093847) evaluating SAMe as adjunct to serotonin reuptake inhibitors in depressed patients. (Papakostas et al. 2010, Am J Psychiatry)

Depressed adults on SSRIs.

SAMe augmentation modestly improved response and remission rates vs placebo when added to SSRIs. Note: depression management primarily uses SSRIs/SNRIs/atypical antidepressants + CBT/psychotherapy. SAMe is a reasonable adjunctive option for partial responders.

2
SAMe Monotherapy for MDD — Phase II RCT
PubMed

Phase II trial (NCT01912196) of SAMe monotherapy (800-1,600 mg/day) vs placebo in 60 patients with MDD.

60 MDD patients.

SAMe modestly reduced depression scores vs placebo as monotherapy. Effect sizes modest. Note: small Phase II — not large definitive trial. SAMe vs SSRI head-to-head trials have shown comparable efficacy in some studies but with substantially higher cost.

3
SAMe vs Celecoxib for Knee OA — RCT
PubMed

RCT (NCT00133341) of SAMe (1,200 mg/day) vs celecoxib (200 mg/day) vs placebo in 120 patients with knee OA. (Najm et al. 2004, BMC Musculoskelet Disord — earlier; or related)

120 knee OA patients.

SAMe and celecoxib produced comparable pain and function improvements vs placebo. Slower onset for SAMe (1 month vs days for celecoxib). Note: NSAID alternatives clinically valuable; SAMe lacks GI/cardiovascular toxicity of NSAIDs.

4
SAMe for Depression in Parkinson's Disease — Open-Label Pilot
PubMed

Pilot, open-label study (NCT00070941) of SAMe (800-2,400 mg/day) in 21 patients with Parkinson's disease and depression.

21 PD + depression patients.

Modest improvements in depression scores. CRITICAL CAVEAT: open-label (no placebo, not blinded) — inflated effect estimate. Pilot only. Note: PD-related depression is challenging; SSRIs first-line; consider drug-drug interactions in PD pharmacotherapy.

Side effects and drug interactions

Common Potential side effects

Gastrointestinal: Nausea, diarrhea, upset stomach, bloating, or mild abdominal pain are frequently reported, especially at higher doses.
Nervous System: Headache, dizziness, or mild insomnia may occur, particularly if taken later in the day due to its potential to increase energy or alertness.
Psychiatric: Anxiety, restlessness, or irritability can occur, especially in sensitive individuals or at high doses.

Important Drug interactions

Antidepressants (MAOIs, SSRIs, SNRIs, tricyclics) — serious serotonin syndrome risk; never combine with MAOIs; use extreme caution with SSRIs
Levodopa — SAMe may reduce levodopa efficacy in Parkinson's disease; avoid concurrent use
Warfarin — SAMe may enhance anticoagulant effects; monitor INR closely
Featured In

Symptom-specific supplement guides

🦴Best Supplements for Joint Pain

More Cognitive Ingredients

Energy
Caffeine
Caffeine, a natural stimulant found in coffee, tea, and other plants, is commonly suppleme…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Cognitive
Vitamin B12
Vitamin B12, also known as cobalamin, is a water-soluble vitamin commonly supplemented as…
Immune Support
Zinc
Zinc, an essential trace mineral, is commonly supplemented in forms like zinc gluconate, a…

Explore Other Ingredients

Antioxidant
NAC (N-Acetylcysteine)
NAC (N-Acetyl Cysteine) is a supplemental form of the amino acid cysteine, best known for…
Antioxidant
Milk Thistle
Milk thistle, derived from the Silybum marianum plant, contains silymarin, a compound know…
Antioxidant
Dandelion Root
Dandelion root is one of the most widely used hepatic and diuretic herbs in Western botani…

Frequently asked questions about SAMe (S-Adenosyl-L-Methionine)

What is SAMe (S-Adenosyl-L-Methionine)?

S-Adenosyl-L-Methionine (SAMe) is a naturally occurring compound in the body, synthesized from methionine and adenosine triphosphate (ATP).

What does SAMe (S-Adenosyl-L-Methionine) do?

SAMe is a universal methyl donor, transferring methyl groups to molecules like DNA, proteins, phospholipids, and neurotransmitters. Modifies DNA and histones to control gene activity. In clinical research, SAMe (S-Adenosyl-L-Methionine) has been studied for mood and depression support, joint health and osteoarthritis, liver function.

Who should take SAMe (S-Adenosyl-L-Methionine)?

SAMe (S-Adenosyl-L-Methionine) may be most relevant for people interested in cognitive, liver health, detox & cleanse. It has been clinically studied for mood and depression support, joint health and osteoarthritis, liver function. As with any supplement, consult your healthcare provider before starting, especially if you have medical conditions or take prescription medications.

How long does SAMe (S-Adenosyl-L-Methionine) take to work?

In clinical trials, effects typically appear over 1+ months of consistent use. Acute or same-day effects (where applicable) typically appear within hours, but most cumulative benefits — particularly those affecting biomarkers, mood, sleep quality, or chronic symptoms — require 4-12 weeks of regular use to fully assess. If you don't notice benefit after 12 weeks at the appropriate dose, it may not be your responder.

When is the best time to take SAMe (S-Adenosyl-L-Methionine)?

For cognitive goals, SAMe (S-Adenosyl-L-Methionine) is typically taken in the morning with breakfast for sustained daytime effects. Avoid late-day dosing if it affects your sleep. Always check product labeling and follow personalized guidance from your healthcare provider.

Is SAMe (S-Adenosyl-L-Methionine) worth taking?

SAMe (S-Adenosyl-L-Methionine) has moderate clinical evidence (Evidence Level 3/5 on NutraSmarts) — meaningful trial support exists, though results are less consistent than top-tier ingredients. Whether it's worth taking depends on your specific goals, what you've already tried, your budget, and your overall supplement strategy. The honest framing: no supplement is essential for most people, and lifestyle factors (sleep, exercise, diet, stress management) typically produce larger effects than any single supplement. SAMe (S-Adenosyl-L-Methionine) is most worth trying if its evidence-supported uses align with your specific goals.

What is the recommended dosage of SAMe (S-Adenosyl-L-Methionine)?

The clinically studied dose for SAMe (S-Adenosyl-L-Methionine) is 400–800 mg/day for depression; 600–1,200 mg/day for osteoarthritis; taken on empty stomach. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is SAMe (S-Adenosyl-L-Methionine) used for?

SAMe (S-Adenosyl-L-Methionine) is studied for mood and depression support, joint health and osteoarthritis, liver function. SAMe may help alleviate symptoms of depression by supporting neurotransmitter production, such as serotonin and dopamine. Studies suggest it can be as effective as some antidepressants for mild-to-moderate depression, with fewer side effects.